Together, these therapies not only help tackle diseases whose pathogenesis is predominantly driven by MAC but also retain the C5a-C5aR1/C5aR2 axis, which may be important for priming innate and adaptive immune cells for fighting infection (Desai et al. 2023; Kim et al. 2004). The gene discussed is C5; the disease is infection.